Concepedia

Author

Réda Bouabdallah

Institut Paoli-Calmettes

Also Known As

Bouabdallah R, Bouabdallah R., Bouabdallah, R., Bouabdallah, Reda, R Bouabdallah, R. BOUABDALLAH, R. Bouabdallah, Reda Bouabdallah, Réda Bouabdallah, RÉDa Bouabdallah

246

Publications

14.5K

Citations

49

H-Index

73

Concepts

All Affiliations

Institut Paoli-CalmettesInsermHôpital Saint-LouisAssistance Publique – Hôpitaux de ParisHospices Civils de Lyon
RB

About

Réda Bouabdallah is an author at Institut Paoli-Calmettes specializing in medicine, immunology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

32

64

4.1K

2

Health Sciences

15

19

1K

3

Engineering

1

1

18

4

Allergy

1

1

10

5

Biostatistics

1

1

18

Réda Bouabdallah

×

118

Publications

13.7K

Citations

47

H-Index

YearCitations

CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

Bertrand Coiffier, Éric Lepage, Josette Brière,

New England Journal of Medicine

2002

5.5K

Treatment of Older Patients with Mantle-Cell Lymphoma

Hanneke C. Kluin‐Nelemans, Eva Hoster, Olivier Hermine,

New England Journal of Medicine

2012

511

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

Thomas E. Witzig, Julie M. Vose, Pier Luigi Zinzani,

Annals of Oncology

2011

392

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

Olivier Hermine, Eva Hoster, Jan Walewski,

The Lancet

2016

390

Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials

Nathalie Mourad, Nicolas Mounier, Josette Brière,

Blood

2008

334

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

Gilles Salles, Nicolas Mounier, Sophie de Guibert,

Blood

2008

330

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo,

The Lancet Haematology

2020

324

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

A.-L. Taksin, Ollivier Legrand, Emmanuel Raffoux,

Leukemia

2006

282

Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome

Bruno Chetaille, François Bertucci, Pascal Finetti,

Blood

2008

250

Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study

Franck Morschhauser, Guillaume Cartron, Catherine Thiéblemont,

Journal of Clinical Oncology

2013

201

Page 1